Acadia Healthcare
ACHC
$25.89
-8.37%
Acadia Healthcare Company, Inc. is a specialized provider of behavioral healthcare services, operating a network of acute inpatient psychiatric facilities, specialty treatment facilities, and residential treatment centers within the healthcare sector. The company is a significant player in the fragmented U.S. behavioral health market, distinguishing itself through a facility acquisition and development model focused on consolidating this space. The current investor narrative is dominated by deep concerns over financial health and turnaround prospects, as highlighted by a major fund's complete exit from its stake, casting doubt on the company's ability to navigate operational challenges and return to sustainable growth.…
ACHC
Acadia Healthcare
$25.89
Related headlines
Investment Opinion: Should I buy ACHC Today?
Rating: Hold. The core thesis is that ACHC is a high-risk, high-reward special situation where explosive technical momentum is clashing with dire fundamentals, creating excessive volatility that favors a cautious, watchful stance rather than a new commitment.
Supporting evidence for this Hold rating includes the stock's 91.6% YTD surge, its low Price-to-Sales ratio of 0.39, and analyst expectations for a swing to positive earnings (forward EPS $1.83, forward P/E ~16.3x). However, these positives are counterbalanced by a -33.29% net margin, a -56.58% ROE, and a high short ratio of 7.06, indicating profound skepticism. The stock trades just 3.9% below its 52-week high, suggesting limited near-term upside before a major technical test.
The two biggest risks are the failure to achieve projected profitability and a reversal of the powerful momentum trade. This Hold would upgrade to a Buy if the stock consolidates and holds above $28.48 on strong volume with confirmation of improving quarterly margins, or if the forward P/E compresses below 12x on sustained earnings growth. It would downgrade to a Sell if the price breaks below key support at $22 (the March consolidation level) on high volume or if quarterly results show net losses widening beyond current estimates. Relative to its own distressed history, the stock appears fairly valued for a turnaround story, but it is not yet undervalued given the execution risk.
Sign up to view all
ACHC 12-Month Price Forecast
The outlook is bifurcated and highly dependent on execution. The explosive rally has pulled forward a significant amount of optimism, leaving little margin for error. The base case of volatile consolidation is most likely, as the market awaits concrete proof that the company can transition from a net loss to substantial profitability. The stance is neutral because the risk/reward is balanced at the current price near the 52-week high. We would upgrade to bullish on a confirmed breakout above $28.48 accompanied by improving quarterly fundamentals. We would downgrade to bearish if the stock loses the $24 support level on deteriorating financial metrics.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Acadia Healthcare's 12-month outlook, with a consensus price target around $33.66 and implied upside of +30.0% versus the current price.
Average Target
$33.66
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$21 - $34
Analyst target range
Analyst coverage for ACHC is limited, with only 3 analysts providing estimates, which is insufficient to derive a meaningful consensus price target or recommendation. This sparse coverage typically indicates the stock is a smaller-cap name (market cap ~$1.29B) with limited institutional research interest, which can contribute to higher volatility and less efficient price discovery. The available data shows estimated EPS for the forward period averaging $1.83, with a narrow range from $1.80 to $1.87, suggesting some agreement on near-term earnings potential, but without price targets, the implied market valuation and upside/downside cannot be calculated. The lack of a target price range and institutional ratings data means there is no clear signal on analyst sentiment, leaving investors with high uncertainty regarding the fundamental assumptions baked into the current stock price following its dramatic recovery.
Bulls vs Bears: ACHC Investment Factors
The investment debate for ACHC is a classic battle between powerful technical momentum and deeply concerning fundamentals. The bull case is driven by an explosive 91.6% YTD rally from oversold levels, a low PS ratio of 0.39, and analyst expectations for a return to profitability (forward EPS $1.83). The bear case is anchored in severe financial distress, evidenced by a -33.29% net margin, a major fund's exit, and a high short ratio of 7.06. Currently, the technical momentum appears stronger, but it is built on fragile fundamental ground. The single most important tension is whether the company can achieve the analyst-projected $1.83 in forward EPS to justify its current valuation and sustain the rally, or if the severe profitability and leverage issues will cause the momentum to reverse sharply.
Bullish
- Explosive Technical Reversal: The stock has surged 91.6% year-to-date and 79.78% over the past 3 months, dramatically outperforming the SPY. This powerful momentum off the 52-week low of $11.43 signals a major reversal from deeply oversold conditions and renewed investor interest.
- Attractive Price-to-Sales Valuation: ACHC trades at a trailing PS ratio of 0.39 and an EV/Sales of 1.58, which are low absolute multiples. This suggests the market is pricing in significant pessimism, offering a potential value opportunity if the company can stabilize its fundamentals.
- Positive Forward Earnings Outlook: Analysts project forward EPS of $1.83, implying a forward P/E of approximately 16.3x. This represents a significant shift from the current trailing net loss (EPS of -$0.86) and is a key catalyst for the stock's recent re-rating.
- Strong Relative Momentum: The stock shows a 3-month relative strength of +76.19% versus the SPY, indicating powerful, stock-specific buying pressure. This momentum, coupled with a beta of 0.71, suggests the rally is driven by idiosyncratic factors rather than broad market moves.
Bearish
- Severe Profitability Crisis: The company is deeply unprofitable with a trailing EPS of -$0.86 and a net margin of -33.29%. The negative Return on Equity of -56.58% signals it is destroying shareholder value, a fundamental red flag that overshadows the recent price rally.
- Major Institutional Vote of No Confidence: Recent news highlights a major fund's complete exit from its $13 million stake, citing deep concerns over financial health and turnaround prospects. This action from a sophisticated investor is a powerful negative signal on the company's near-term outlook.
- High Financial Leverage: A debt-to-equity ratio of 1.36 indicates significant reliance on debt financing. This leverage amplifies risks in a high-interest rate environment and pressures cash flow, which is critical for a company currently reporting negative earnings.
- Extreme Short Interest: A short ratio of 7.06 indicates very high bearish sentiment among short sellers. This creates a persistent overhang and potential for violent squeezes or declines, reflecting deep skepticism about the sustainability of the recent rally.
ACHC Technical Analysis
The stock is in a powerful recovery phase from deeply oversold levels, with a 1-year price change of 23.44% and a staggering 91.60% year-to-date gain as of April 24, 2026. Currently trading at $27.38, the price sits near the top of its 52-week range of $11.43 to $28.48, indicating strong momentum but also proximity to a major technical resistance level that could trigger consolidation. Recent momentum has been exceptionally strong and is accelerating relative to the longer-term trend, with a 79.78% surge over the past 3 months and a 12.63% gain over the past month, far outpacing the SPY's 3.59% and 8.7% returns over the same periods, respectively. This explosive short-term rally suggests a powerful reversal from the prior downtrend, potentially driven by oversold conditions and renewed speculative interest. Key technical support is anchored at the 52-week low of $11.43, while immediate resistance is at the 52-week high of $28.48; a decisive breakout above $28.48 would confirm the new uptrend's strength, while a failure could signal a double-top pattern. The stock's beta of 0.71 indicates it has been less volatile than the broader market during this data period, which is notable given its dramatic price swings, suggesting its moves may be driven more by idiosyncratic factors than systemic risk.
Beta
0.71
0.71x market volatility
Max Drawdown
-61.5%
Largest decline past year
52-Week Range
$11-$29
Price range past year
Annual Return
+10.7%
Cumulative gain past year
| Period | ACHC Return | S&P 500 |
|---|---|---|
| 1m | +10.7% | +10.5% |
| 3m | +92.7% | +3.9% |
| 6m | +20.4% | +5.4% |
| 1y | +10.7% | +29.6% |
| ytd | +81.2% | +5.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ACHC Fundamental Analysis
Revenue trajectory analysis is constrained as specific quarterly revenue and growth rate figures are not available in the provided data; however, analyst estimates point to expected annual revenue of approximately $4.20 billion, indicating the company operates at a significant scale within its industry. The company is currently unprofitable on a net income basis, with a trailing EPS of -$0.86 and a deeply negative net margin of -33.29%, highlighting severe bottom-line challenges. Positively, the operating margin of 11.71% and gross margin of 17.61% suggest the core service delivery can generate operating profit, but significant costs below that line are eroding earnings. Balance sheet health shows a leveraged position with a debt-to-equity ratio of 1.36, indicating reliance on debt financing, while a current ratio of 1.55 suggests adequate short-term liquidity to meet obligations. The negative return on equity of -56.58% is a major red flag, signaling the company is destroying shareholder value based on its reported earnings, and the lack of free cash flow data limits the assessment of internal funding capacity for growth or debt reduction.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ACHC Overvalued?
Given the negative trailing Net Income (EPS of -$0.86), the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 0.39 and an EV/Sales multiple of 1.58, which are low absolute multiples that typically reflect market skepticism about growth or profitability prospects. Peer comparison data for the industry is not available in the provided dataset, preventing a quantitative assessment of whether ACHC trades at a premium or discount to its sector; this absence of context makes it difficult to judge relative value. Historical context for the stock's own valuation ratios is also not available, so it is impossible to determine if the current PS ratio of 0.39 is near the top or bottom of its historical range, obscuring whether it represents a value opportunity or is pricing in continued fundamental deterioration.
PE
-1.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-5.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe. The company is burning through shareholder value with a -56.58% ROE and a -33.29% net margin, indicating fundamental profitability is broken. A debt-to-equity ratio of 1.36 creates significant financial leverage, increasing vulnerability to rising interest costs and limiting flexibility. The lack of free cash flow data obscures the company's ability to fund operations or service debt internally, making it dependent on external financing or asset sales.
Market & Competitive Risks are elevated. The stock's dramatic 91.6% YTD run places it near its 52-week high of $28.48, facing major technical resistance. With a beta of 0.71, its moves are somewhat insulated from the market, but this also means its recent outperformance is purely stock-specific and could reverse abruptly. The high short ratio of 7.06 represents a concentrated pool of capital betting against the company, which can lead to increased volatility. The major fund's complete exit, as reported, underscores a loss of confidence from sophisticated investors that could deter other institutional buyers.
The Worst-Case Scenario involves the company failing to achieve its projected turnaround. If forward EPS of $1.83 is missed and net losses persist, the recent momentum-driven rally would likely collapse. A re-test of the 52-week low of $11.43 is plausible, representing a downside of approximately -58% from the current price of $27.38. This could be triggered by a disappointing earnings report, a credit rating downgrade due to its leveraged balance sheet, or a broader sector sell-off. The historical max drawdown of -61.48% provides a benchmark for the magnitude of loss possible in a full bear case realization.
FAQ
The key risks are, in order of severity: 1) Financial Risk: The company is destroying shareholder value (ROE -56.58%) and carries significant debt (D/E 1.36), risking a liquidity crisis if losses continue. 2) Execution Risk: The entire investment thesis hinges on achieving analyst-projected EPS of $1.83; any shortfall could crash the stock. 3) Sentiment Risk: High short interest (short ratio 7.06) and the recent exit of a major fund create a negative overhang and potential for violent price swings. 4) Technical Risk: After a 91.6% YTD rally, the stock is near major resistance at $28.48, increasing the probability of a sharp pullback or consolidation.
The 12-month forecast is highly uncertain, with three distinct scenarios. The Base Case (50% probability) sees the stock oscillating between $24 and $28 as it digests its massive gains, awaiting proof of a profitability turnaround. The Bull Case (25% probability) projects a breakout above $28.48 toward a range of $32-$38, driven by successful execution of the $1.83 EPS target and short covering. The Bear Case (25% probability) warns of a collapse back toward the $11-$18 range if quarterly losses persist, invalidating the turnaround narrative. The Base Case is most likely, as the market requires several quarters of evidence to confirm the fundamental improvement.
ACHC's valuation presents a paradox. On a Price-to-Sales basis at 0.39x, it appears deeply undervalued, suggesting the market has priced in permanent distress. However, based on earnings, it is uninvestable with a negative trailing P/E. The forward P/E of approximately 16.3x (based on $1.83 EPS) is reasonable for a healthcare services company, but this assumes a successful and dramatic turnaround from net losses. Therefore, the stock is fairly valued for the high-risk, high-reward turnaround scenario it represents. It is not cheap given the execution risk, nor is it expensive if the earnings projections materialize.
ACHC is not a good buy for most conservative or income-oriented investors due to its severe profitability issues and high volatility. For speculative investors with a high risk tolerance, it presents a potential turnaround story trading at a low PS ratio of 0.39, with analyst projections pointing to positive forward EPS of $1.83. However, the 91.6% YTD rally has likely priced in much of the near-term optimism, and the downside risk to the 52-week low of $11.43 (-58%) is substantial. It could be a good buy only on a significant pullback that offers a better margin of safety, or after a confirmed breakout above $28.48 with supporting fundamental improvements.
ACHC is unsuitable for short-term trading for all but the most experienced tactical traders due to its extreme volatility and low beta (0.71), which can lead to unpredictable, stock-specific moves. As a long-term investment, it is a highly speculative turnaround bet that requires a 3-5 year horizon to see if management can successfully repair the balance sheet and return to sustainable profitability. The lack of a dividend further removes any income rationale for holding. The minimum suggested holding period is 12-18 months to fully assess the validity of the forward earnings projections through multiple quarterly reports.